Spanish real-world experience with belumosudil for chronic graft-versus-host disease after two or more prior lines of therapy.

Rebeca Bailén; Felipe Peña-Muñoz; A. Insunza; Lucía Lopez-Corral; Laura Maria Fox; Carlos de Miguel; Pedro Asensi; Juan Martín-González; María Jesús Pascual-Cascón; Mary DeRome; Pedro Antonio González Sierra; Isabel Izquierdo; Xavier Ortı́n; Judith Vázquez; Candela Ceballos; Alejandro Morales-Curbelo; Andres Sanchez-Salinas; Joud Zanabili; Luisa Sisinni; Marta Gonzalez-Vicent; Lucía Castilla; Pascual Balsalobre; Mi Kwon; On Behalf Of Grupo Español de Trasplante Hematopoyético Y Terapia Celular Geth

doi:10.1016/j.jtct.2026.03.001

Key Points

The aim is to evaluate the safety and efficacy of belumosudil in patients with chronic graft-versus-host disease after multiple therapies.
Real-world experience analysis of heavily treated patients
Assessment of cGVHD severity
Monitoring safety and efficacy profiles
Belumosudil demonstrated a favorable safety profile
Efficacy was confirmed in patients who had undergone two or more treatments
Most patients had severe cGVHD symptoms but responded positively

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Real-world experience confirms safety and efficacy of belumosudil for chronic graft-versus-host disease in heavily pretreated patients.

Abstract

. Our real-world experience, involving heavily pretreated patients with predominantly severe cGVHD, confirms the safety and efficacy profile of belumosudil.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bailén et al. (2026) studied this question.

synapsesocial.com/papers/69af95de70916d39fea4dda4 https://doi.org/10.1016/j.jtct.2026.03.001

View at Publisher

Ask AI

Bookmark

Share

Spanish real-world experience with belumosudil for chronic graft-versus-host disease after two or more prior lines of therapy.

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Spanish real-world experience with belumosudil for chronic graft-versus-host disease after two or more prior lines of therapy.

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading